Michael Williams
All articles

Everything by Michael.

1,135 articles

← Back to profile
Investing

BSTZ Holds Over 30% in Illiquid Private Companies and Trades at an 11.4% NAV Discount

Apr 1, 2026
Investing

ULTY Pays Weekly but Its Share Price Fell 47.14% While the S&P 500 Gained 19%

Apr 1, 2026
Investing

MAGS ETF: Two Signals Will Determine If the 16% Slide Gets Worse in 2026

Mar 31, 2026
Investing

ONEQ Is Down 10% in 2026 and Nvidia Holds the Key to What Comes Next

Mar 31, 2026
Investing

Fidelity Disruptive Technology ETF Is Down 12% in 2026 and This Catalyst Could Decide What Comes Next

Mar 31, 2026
Investing

Vanguard’s VXF Captured 194% Over 10 Years While Holding Stocks the S&P 500 Ignores

Mar 31, 2026
Investing

Fidelity Blue Chip Growth Is Down 11.67% in 2026. What Comes Next Depends on This.

Mar 31, 2026
Investing

AVUS Outpaced VTI by 16 Points Over 5 Years. Is It the Better Core Holding?

Mar 31, 2026
Investing

XLC Is Down 8.78% Year to Date and the Catalysts That Matter Most Are Still Ahead

Mar 31, 2026
Investing

Tencent’s 16% Weight and the Tariff Cycle Will Decide MCHI’s 2026

Mar 31, 2026
Investing

FFEM Dropped 13% in One Month as Rising Treasury Yields Drain Emerging Markets

Mar 31, 2026
Investing

TOPT Holds 16% in NVIDIA Alone, and That Concentration Is Driving Its 11% Loss

Mar 30, 2026
Investing

MOAT ETF Is Down 7% in 2026. Here Is the Macro Signal That Changes Everything

Mar 30, 2026
Investing

The Low-Volatility Promise of ACWV Costs Investors 118% Over a Decade Compared to SPY

Mar 30, 2026
Investing

ACWI’s 18.3% Run Beat the S&P 500, But the 10-Year Story Is More Complicated

Mar 30, 2026
Investing

XSD Investors: Intel’s Foundry Losses and AI Spending Are the Signals to Watch

Mar 30, 2026
Investing

Vanguard’s MGC Has Returned 297% Over 10 Years, But Is It Really Conservative?

Mar 30, 2026
Investing

Why Conservative Investors Are Turning to AOK With VIX at the 93rd Percentile

Mar 29, 2026
Investing

$31.7 Billion in Assets and a 0.05% Fee: Is Vanguard’s VOT Actually Worth Holding?

Mar 29, 2026
Investing

MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance

Mar 29, 2026